20 news...
1. Intellia Therapeutics Shares Under Pressure as FDA Halt Persists
2025-12-07 16:53:05
Intellia Therapeutics US45826J1051
Intellia Therapeutics continues to face significant headwinds in the market. The focus for the Cambridge-based biotech firm remains squarely on resolving a clinical hold imposed by the U.S. Food and Drug Administration...score:0.561, 2025-12-07 19:11:53
2. Intellia Therapeutics Investors Await Critical FDA Verdict
2025-12-04 14:11:05
Intellia Therapeutics US45826J1051
The current trading pattern of Intellia Therapeutics shares, hovering nervously around $8.12, belies the intense pressure building within the company. A state of anxious anticipation has gripped the market as...ad-hoc-news.de ...
score:0.501, 2025-12-04 16:31:41
3. Intellia Therapeutics Faces Investor Exodus After Clinical Trial Fatality
2025-12-03 16:44:04
Intellia Therapeutics US45826J1051
Shares of Intellia Therapeutics are experiencing a severe, foundation-shaking sell-off following a critical safety development in a late-stage trial. Investor confidence has evaporated after the company confirmed a...ad-hoc-news.de ...
score:0.522, 2025-12-03 19:49:40
4. Intellia Therapeutics Faces Regulatory Hurdle and Mixed Financial Results
2025-12-02 08:25:05
Intellia Therapeutics US45826J1051
The pioneering gene-editing firm Intellia Therapeutics is navigating a period of significant pressure. A clinical hold imposed by U.S. regulators on its lead program and a quarterly earnings report with both positive...ad-hoc-news.de ...
score:0.577, 2025-12-02 10:43:31
5. Intellia Therapeutics Faces Critical Juncture as Clinical Trial Halt Sparks Downgrade
2025-12-01 20:52:05
Intellia Therapeutics US45826J1051
Intellia Therapeutics shares opened the week under significant pressure, trading around $9.00 at the market open. This price level places the stock far from its 52-week highs, reflecting mounting investor skepticism...ad-hoc-news.de ...
score:0.546, 2025-12-01 23:06:48
6. Intellia Therapeutics: A High-Stakes Investment Gamble
...
ad-hoc-news.de ...
score:0.536, 2025-11-29 19:33:06
7. Clinical Trial Halt Sends Intellia Therapeutics Shares Reeling
...
ad-hoc-news.de ...
score:0.527, 2025-11-28 16:14:17
8. Viking Therapeutics Stock Surges on Clinical Trial Milestone
...
ad-hoc-news.de ...
score:0.516, 2025-11-25 11:29:00
9. Arrowhead Pharmaceuticals Emerges as Biotech Powerhouse
...
ad-hoc-news.de ...
score:0.518, 2025-11-25 08:25:46
10. Intellia Therapeutics Faces Critical Juncture Following Clinical Trial Setback
...
ad-hoc-news.de ...
score:0.54, 2025-11-21 09:33:40
11. Assembly Biosciences: A High-Stakes Bet on Antiviral Innovation
...
ad-hoc-news.de ...
score:0.505, 2025-11-19 08:37:26
12. Intellia Therapeutics Faces Severe Setback Following Clinical Trial Death
...
ad-hoc-news.de ...
score:0.541, 2025-11-17 07:16:40
13. Clinical Trial Setback Sends Intellia Therapeutics Shares into Decline
...
ad-hoc-news.de ...
score:0.531, 2025-11-16 08:02:39
14. Brainstorm Cell Therapeutics: A Pivotal Week for Its ALS Therapy and Finances
...
ad-hoc-news.de ...
score:0.505, 2025-11-15 09:32:49
15. Larimar Therapeutics Stock: Navigating Volatility Amid Clinical Promise
...
ad-hoc-news.de ...
score:0.53, 2025-11-14 10:09:37
16. BioAge Labs Stock: Navigating Turbulent Waters After Q3 Earnings
...
ad-hoc-news.de ...
score:0.512, 2025-11-13 17:07:13
17. Sangamo Therapeutics: Navigating a Critical Financial Crossroads
...
ad-hoc-news.de ...
score:0.508, 2025-11-13 13:04:29
18. Intellia Therapeutics Shares Plunge on Clinical Trial Setbacks
...
ad-hoc-news.de ...
score:0.553, 2025-11-12 09:12:55
19. Intellia Therapeutics Faces Critical Juncture Following Patient Death
...
ad-hoc-news.de ...
score:0.505, 2025-11-11 17:34:36
20. Intellia Therapeutics Faces Critical Regulatory Hurdle Despite Promising Trial Data
...
ad-hoc-news.de ...
score:1, 2025-11-11 08:25:01